TŽTamara Žigman

Tamara Žigman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tamara Žigman has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Asparagine Synthetase Deficiency: Neuropathological Evidence of Disrupted Cortical Development

    by Mihaela Bobić, Goran Sedmak, Ema Bokulić, Tila Medenica, Tamara Žigman, Bernarda Medlobi Vinković, Viktorija Antolović, Nenad Kešin, Ivan Lehman, Ana Škaričić, et al.

    Asparagine synthetase deficiency (ASNSD) is a rare metabolic disease causing congenital microcephaly, severe developmental delay, and spastic quadriplegia. Although the central nervous system is severely affected, other organ systems appear unaffected by asparagine deficiency. We present an infant homozygous for the mutation c.904‐1G>A in the ASNS gene, whose clinical presentation and radiological findings were typical for ASNSD. Following the patient's death at the age of 6 months, histological and immunohistochemical examination of the telencephalon revealed a vast disturbance of migration of neuronal subpopulations, consequently severe disorganization of cortical layers, and thinning of the cerebral cortex. These findings provide novel insights into disease pathogenesis and may explain the hallmark features of ASNSD, including microcephaly and epilepsy.


  • Open Access

    The Application of the NGS and MLPA Methods in the Molecular Diagnostics of Lynch Syndrome

    by Ivana Rako, Ema Vinceljak, Marina Popovic, Tamara Zigman

    Background: Lynch syndrome (LS) is a cancer-susceptibility syndrome associated with autosomal dominant predisposition to a spectrum of cancers, primarily of the colorectum and endometrium, which exhibit impaired DNA mismatch repair (MMR) activity. LS is caused by a hereditary (germline) pathogenic (PV) or likely pathogenic variant (LPV) in one of the mismatch repair (MMR) genes—MLH1, MSH2, MSH6, PMS2, or EPCAM. Although point mutations are the most common genetic changes in MMR genes, >20% are large genomic rearrangements. We hypothesized that a two-tier diagnostic strategy for Lynch syndrome (LS) using next generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) can increase diagnostic yield of patients with Lynch syndrome. Methods: This study included 60 patients suspected of LS. After genetic counseling, they were referred to genetic testing. Genomic DNA was extracted from peripheral blood and sequenced using NGS multigene panel testing covering 113 cancer susceptibility genes, including MMR genes. Regarding limitations of NGS analysis, which cannot reliably detect genomic alterations larger than 50 base pairs in length, the MLPA method was used for NGS negative DNA samples in order to identify larger deletions and duplications, commonly referred to as copy number variations (CNVs). Results: Different PVs were detected by NGS in 10 patients and CNVs were detected by MLPA in 7 more patients: 3xMLH1 del ex9-15, 2xMSH2 del ex1 and upstream, 1xMSH2 del ex9, and 1xMSH2 del ex1. We did not detect LPVs or variants of uncertain significance (VUS). In our cohort, the addition of MLPA provided an incremental yield of seven pathogenic CNVs, representing an 11.6% absolute increase in diagnostic sensitivity (from 16.7% to 28.3%) over the NGS-alone workflow, with CNVs accounting for 41% of all pathogenic findings. Conclusions: Our results show that MLPA is a very useful method in molecular diagnostics of LS and its implementation in routine genetic testing in combination with NGS using multigene panel testing would benefit both patients and health care providers.


  • X-linked FLNA mutation with valvular dysplasia

    by Marija Tomac Stojmenović, Irena Ivanac Vranešić, Tamara Žigman, Jadranka Šeparović Hanževački, Neven Čače, Vlatka Rešković Lukšić

  • Dominant rhabdomyolysis linked to a recurrent ATP2A2 variant reducing SERCA2 function in muscle

    by Sivasankar Malaichamy, Romane Idoux, Kiran Polavarapu, Katarina Šikić, Elisa Holla, Rachel Thompson, Sally Spendiff, Anne Schänzer, Benno Küsters, Emily Freeman, et al.

    Rhabdomyolysis is an acute failure of cellular homeostasis resulting in muscle breakdown, triggered by trauma, infection, drugs or strenuous exercise. Recurrent rhabdomyolysis is often associated with genetic and metabolic defects of skeletal muscle. The sarcoendoplasmic reticulum Ca2+-ATPase 2 (SERCA2), encoded by the ATP2A2 gene, is an intracellular pump located in the sarcoplasmic and endoplasmic reticulum that is essential for maintaining intracellular calcium (Ca2+) homeostasis and is highly expressed in slow-twitch muscle. Heterozygous loss-of-function variants in ATP2A2 have previously been associated with dominant skin diseases, but not with rhabdomyolysis. In this study, we report a rare novel heterozygous missense variant in the ATP2A2 gene (c.1583G>A, p.R528Q) identified in 14 affected individuals from three unrelated families with recurrent rhabdomyolysis. Muscle biopsy revealed mild myopathic changes with fibre type uniformity, core-like structures and Z-band streaming, but normal levels of SERCA2 protein. Ca2+ imaging showed that sarcoplasmic reticulum Ca2+ reuptake mediated by SERCA was significantly slower in myotubes derived from patient fibroblasts carrying the c.1583G > A variant. We hypothesize that the ATP2A2 variant impairs SERCA2a function in slow-twitch muscle, disrupting SR Ca2+ reuptake and causing cytosolic Ca2+ overload following a trigger, leading to recurrent rhabdomyolysis. Morphant zebrafish embryos with atp2a2a knockdown showed morphological and functional muscle abnormalities, with a reduction in body length and trunk muscle area associated with a reduction in locomotor activity in zebrafish larvae. Co-injection of wild-type human SERCA2a mRNA, but not variant SERCA2a mRNA, resulted in complete rescue of the phenotype. This study reveals a novel association between a heterozygous ATP2A2 variant and autosomal dominant recurrent rhabdomyolysis. Both in vitro and in vivo studies provide evidence that the variant alters SERCA2 function, causing abnormal intracellular Ca2+ homeostasis in skeletal muscle, resulting in rhabdomyolysis. The work not only increases understanding of autosomal dominant rhabdomyolysis but also provides a diagnostic conclusion for three generations of affected individuals across the three families.


  • Open Access

    Dilemmas in genetic diagnostics of inborn errors of metabolism and how to help yourself

    by Tamara Žigman, Danijela Petković Ramadža

    Genske analize omogućuju definiranje molekularne osnove nasljedne metaboličke bolesti, usmjeravaju nas prema optimalnom načinu liječenja i omogućuju genetičko informiranje, a ponekad i prenatalnu dijagnostiku, ako je indicirana. Ulaskom tehnologije s...


  • Open Access

    Epilepsies and epileptic encephalopathies due to inborn errors of metabolism

    by Tamara Žigman, Danijela Petković Ramadža, Ivo Barić

    Epileptički napadaji mogu biti simptom velikog broja nasljednih metaboličkih bolesti, a metaboličke epilepsije pripadaju različitim skupinama nasljednih metaboličkih bolesti. Epilepsija je čest simptom kod poremećaja energetskog metabolizma, poremeća...

  • Aortic dilatation and miscarriages as a main presentation of FLNA mutation in a Croatian family – case report, part two

    by Marija Tomac Stojmenović, Vlatka Rešković Lukšić, Irena Ivanac Vranešić, Velena Radošević, Tamara Žigman, Maja Hrabak Paar, Jadranka Šeparović Hanževački

  • Results of the clinical genetic testing pilot study for cardiomyopathies conducted in Dubrava University Hospital

    by Mario Udovičić, Ana Livun, Željko Sutlić, Rajko Kušec, Danijela Grizelj, Tamara Žigman, Katica Cvitkušić Lukenda, Diana Rudan, Šime Manola

  • Genetic counselling unit- model and experience of University Hospital for Tumours in Croatia

    by Iva Kirac, Tamara Zigman, Ramic Snjezana, Tomislav Oresic, Ivan Milas, Danko Velimir Vrdoljak

  • ATP synthase deficiency due to m.8528T>C mutation – a novel cause of severe neonatal hyperammonemia requiring hemodialysis

    by Tamara Žigman, Katarina Šikić, Danijela Petković Ramadža, Johannes Mayr, Saskia Wortmann, Holger Prokisch, Dorotea Ninković, Daniel Dilber, Dalibor Šarić, Filip Rubić, et al.

    Objectives: Hyperammonemia in a newborn is a serious condition, which requires prompt intervention as it can lead to severe neurological impairment and death if left untreated. The most common causes of hyperammonemia in a newborn are acute liver failure and inherited metabolic disorders. Several mitochondrial disorders have been described as a cause of severe neonatal hyperammonemia. Case presentation: Here we describe a new case of adenosine-triphosphate (ATP) synthase deficiency due to m.8528T>C mutation as a novel cause of severe neonatal hyperammonemia. So far six patients with this mutation have been described but none of them was reported to need hemodialysis in the first days of life. Conclusion: This broadens the so far known differential diagnosis of severe neonatal hyperammonemia requiring hemodialysis.